ID

11787

Descrizione

Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia; ODM derived from: http://clinicaltrials.gov/show/NCT02034227

collegamento

http://clinicaltrials.gov/show/NCT02034227

Keywords

versioni (3)
  1. 03/08/15 03/08/15 - Julian Varghese
  2. 03/08/15 03/08/15 - Julian Varghese
  3. 20/09/21 20/09/21 -
Caricato su

3 agosto 2015

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Acute Myeloid Leukemia NCT02034227

Inglese

Eligibility Acute Myeloid Leukemia NCT02034227

1 moduli  
  1. StudyEvent: Eligibility Acute Myeloid Leukemia NCT02034227
    1. Eligibility Acute Myeloid Leukemia NCT02034227
Inclusion Criteria
Descrizione

Inclusion Criteria

male or female greater than or equal to 18 years of age
Descrizione

male or female greater than or equal to 18 years of age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
have one of the following disease states: acute myeloid leukemia (aml) (age <60 years) with relapsed/refractory disease; chronic lymphocytic leukemia (cll) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimen
Descrizione

have one of the following disease states: acute myeloid leukemia (aml) (age <60 years) with relapsed/refractory disease; chronic lymphocytic leukemia (cll) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimen

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0205269
UMLS CUI [2,1]
C0023467
UMLS CUI [2,2]
C0035020
UMLS CUI [3]
C0001779
UMLS CUI [4,1]
C0278787
UMLS CUI [4,2]
C0332293
UMLS CUI [4,3]
C0059985
UMLS CUI [5,1]
C0023434
UMLS CUI [5,2]
C0332293
UMLS CUI [5,3]
C0002073
are recovered from the acute adverse effects of prior therapies (excluding alopecia and grade ≤2 neuropathy).
Descrizione

are recovered from the acute adverse effects of prior therapies (excluding alopecia and grade ≤2 neuropathy).

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2004454
UMLS CUI [1,2]
C0879626
UMLS CUI [2]
C0002170
UMLS CUI [3]
C0442874
have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000 mg daily).
Descrizione

have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000 mg daily).

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1318023
UMLS CUI [1,2]
C0332298
UMLS CUI [1,3]
C0020402
have adequate hepatic function and renal function
Descrizione

have adequate hepatic function and renal function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1848676
UMLS CUI [2]
C0232805
have an estimated life expectancy of >3 months
Descrizione

life expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
female subject must have a negative serum pregnancy result within 7 days before the start of the study; both men and women must agree to use a medically acceptable form of contraception throughout the treatment period and for 3 months after discontinuation of treatment
Descrizione

female subject must have a negative serum pregnancy result within 7 days before the start of the study; both men and women must agree to use a medically acceptable form of contraception throughout the treatment period and for 3 months after discontinuation of treatment

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0420837
UMLS CUI [2]
C0430064
Exclusion Criteria
Descrizione

Exclusion Criteria

are eligible for any standard therapy known to be life prolonging or life saving
Descrizione

are eligible for any standard therapy known to be life prolonging or life saving

Tipo di dati

boolean

have diagnosis of aml french-american-british (fab) classification (fab) m3 (acute promyelocytic leukemia (apl))
Descrizione

have diagnosis of aml french-american-british (fab) classification (fab) m3 (acute promyelocytic leukemia (apl))

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0457329
are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or hormonal treatment for cancer.
Descrizione

are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or hormonal treatment for cancer.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3665472
UMLS CUI [2]
C1522449
UMLS CUI [3]
C0021083
UMLS CUI [4]
C1531518
UMLS CUI [5]
C0279025
have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of other investigational agents within 4 weeks before study entry.
Descrizione

have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of other investigational agents within 4 weeks before study entry.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3665472
UMLS CUI [2]
C0279025
UMLS CUI [3]
C0021083
UMLS CUI [4]
C0020402
prior radiation therapy with volume of bone marrow treated over 25%.
Descrizione

prior radiation therapy with volume of bone marrow treated over 25%.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
use of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of sg2000.
Descrizione

use of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of sg2000.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0455630
UMLS CUI [2]
C0149783
hyperleukocytosis (blast counts >30 000/mm3).
Descrizione

hyperleukocytosis (blast counts >30 000/mm3).

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3805210
history of allogeneic stem cell or solid organ transplantation.
Descrizione

history of allogeneic stem cell or solid organ transplantation.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0029216
UMLS CUI [2]
C2242529
positive serology for human immunodeficiency virus (hiv), hepatitis b or hepatitis c or have hiv-aids, or active hepatitis b or c.
Descrizione

positive serology for human immunodeficiency virus (hiv), hepatitis b or hepatitis c or have hiv-aids, or active hepatitis b or c.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0744837
UMLS CUI [3]
C0850489
UMLS CUI [4]
C0001175
history of other invasive malignancy within 3 years except for cervical carcinoma in situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has been surgically cured.
Descrizione

history of other invasive malignancy within 3 years except for cervical carcinoma in situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has been surgically cured.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0677898
UMLS CUI [2]
C0007099
UMLS CUI [3,1]
C0007114
UMLS CUI [3,2]
C1518408
have any coexisting medical condition that will substantially increase the risk associated with the subject's participation in the study.
Descrizione

have any coexisting medical condition that will substantially increase the risk associated with the subject's participation in the study.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C1549479
UMLS CUI [1,3]
C0012634
have psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of necessary studies.
Descrizione

have psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of necessary studies.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1549479
UMLS CUI [1,3]
C0004936
have persistent grade 2 or greater toxicities from any cause (except alopecia or peripheral neuropathy).
Descrizione

have persistent grade 2 or greater toxicities from any cause (except alopecia or peripheral neuropathy).

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2826262
UMLS CUI [2]
C0002170
UMLS CUI [3]
C0031117
are pregnant or breast-feeding.
Descrizione

are pregnant or breast-feeding.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0549206
UMLS CUI [2]
C0006147
Ritorna all'inizio della pagina

Similar models

Eligibility Acute Myeloid Leukemia NCT02034227

1 moduli
  1. StudyEvent: Eligibility Acute Myeloid Leukemia NCT02034227
    1. Eligibility Acute Myeloid Leukemia NCT02034227
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Age
Item
male or female greater than or equal to 18 years of age
boolean
C0001779 (UMLS CUI [1])
Leukemia, Myelocytic, Acute; Unresponsive to Treatment | Leukemia, Myelocytic, Acute; Relapse | Age | chronic myelogenous leukemia in relapse; Treated with; fludarabine | Chronic Lymphocytic Leukemia; Treated with; Alkylating Agents
Item
have one of the following disease states: acute myeloid leukemia (aml) (age <60 years) with relapsed/refractory disease; chronic lymphocytic leukemia (cll) with relapsed disease following a fludarabine-based regimen or relapsed disease following an alkylator-based regimen
boolean
C0023467 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0023467 (UMLS CUI [2,1])
C0035020 (UMLS CUI [2,2])
C0001779 (UMLS CUI [3])
C0278787 (UMLS CUI [4,1])
C0332293 (UMLS CUI [4,2])
C0059985 (UMLS CUI [4,3])
C0023434 (UMLS CUI [5,1])
C0332293 (UMLS CUI [5,2])
C0002073 (UMLS CUI [5,3])
Recovery from ; Alopecia Adverse Event | Neuropathy; Adverse event
Item
are recovered from the acute adverse effects of prior therapies (excluding alopecia and grade ≤2 neuropathy).
boolean
C2004454 (UMLS CUI [1,1])
C0879626 (UMLS CUI [1,2])
C0002170 (UMLS CUI [2])
C0442874 (UMLS CUI [3])
Blast cell count measurement; Controlled by; hydroxyurea
Item
have blast counts that can be controlled by the use of hydroxycarbamide (500 to 3000 mg daily).
boolean
C1318023 (UMLS CUI [1,1])
C0332298 (UMLS CUI [1,2])
C0020402 (UMLS CUI [1,3])
adequate hepatic function; renal function
Item
have adequate hepatic function and renal function
boolean
C1848676 (UMLS CUI [1])
C0232805 (UMLS CUI [2])
life expectancy
Item
have an estimated life expectancy of >3 months
boolean
C0023671 (UMLS CUI [1])
Contraception status | serum pregnancy test
Item
female subject must have a negative serum pregnancy result within 7 days before the start of the study; both men and women must agree to use a medically acceptable form of contraception throughout the treatment period and for 3 months after discontinuation of treatment
boolean
C0420837 (UMLS CUI [1])
C0430064 (UMLS CUI [2])
Eligibility for lifesaving or life-prolonging standard therapy
Item
are eligible for any standard therapy known to be life prolonging or life saving
boolean
FAB type M3
Item
have diagnosis of aml french-american-british (fab) classification (fab) m3 (acute promyelocytic leukemia (apl))
boolean
C0457329 (UMLS CUI [1])
Chemotherapy | Therapeutic radiology procedure | Immunotherapy | Biological treatment | Hormone Therapy
Item
are receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or hormonal treatment for cancer.
boolean
C3665472 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C1531518 (UMLS CUI [4])
C0279025 (UMLS CUI [5])
Chemotherapy | Hormone Therapy | Immunotherapy | hydroxyurea
Item
have undergone anticancer therapy including chemotherapy (except for hydroxycarbamide at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of other investigational agents within 4 weeks before study entry.
boolean
C3665472 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0020402 (UMLS CUI [4])
Therapeutic radiology procedure; Bone Marrow; Percent (qualifier value)
Item
prior radiation therapy with volume of bone marrow treated over 25%.
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
History of immunosuppressive therapy | Steroid therapy
Item
use of immunosuppressive therapy, including systemic steroids within 7 days before the first dose of sg2000.
boolean
C0455630 (UMLS CUI [1])
C0149783 (UMLS CUI [2])
hyperleukocytosis
Item
hyperleukocytosis (blast counts >30 000/mm3).
boolean
C3805210 (UMLS CUI [1])
Organ Transplantation | Allogeneic Stem Cell Transplantation
Item
history of allogeneic stem cell or solid organ transplantation.
boolean
C0029216 (UMLS CUI [1])
C2242529 (UMLS CUI [2])
HIV Seropositivity | hepatitis b serology | hepatitis C serology test | Acquired Immunodeficiency Syndrome
Item
positive serology for human immunodeficiency virus (hiv), hepatitis b or hepatitis c or have hiv-aids, or active hepatitis b or c.
boolean
C0019699 (UMLS CUI [1])
C0744837 (UMLS CUI [2])
C0850489 (UMLS CUI [3])
C0001175 (UMLS CUI [4])
invasive cancer | Carcinoma in Situ | Malignant neoplasm of skin; Nonmelanomatous
Item
history of other invasive malignancy within 3 years except for cervical carcinoma in situ, nonmelanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has been surgically cured.
boolean
C0677898 (UMLS CUI [1])
C0007099 (UMLS CUI [2])
C0007114 (UMLS CUI [3,1])
C1518408 (UMLS CUI [3,2])
Study Subject Participation Status; limited by - ActRelationshipType; Disease
Item
have any coexisting medical condition that will substantially increase the risk associated with the subject's participation in the study.
boolean
C2348568 (UMLS CUI [1,1])
C1549479 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
Informed Consent; limited by - ActRelationshipType; Mental disorders
Item
have psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of necessary studies.
boolean
C0021430 (UMLS CUI [1,1])
C1549479 (UMLS CUI [1,2])
C0004936 (UMLS CUI [1,3])
Toxicity Grade | Alopecia | Peripheral Neuropathy
Item
have persistent grade 2 or greater toxicities from any cause (except alopecia or peripheral neuropathy).
boolean
C2826262 (UMLS CUI [1])
C0002170 (UMLS CUI [2])
C0031117 (UMLS CUI [3])
Patient currently pregnant | Breast Feeding
Item
are pregnant or breast-feeding.
boolean
C0549206 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial